Literature DB >> 8240728

Does proof of casualty ever exist in pharmacovigilance?

M Auriche1, E Loupi.   

Abstract

Identifying the adverse effects of drugs, thus transforming adverse events into adverse drug reactions, is a useful and necessary but complicated task. Objective proof of a causal relationship between a drug and a specific event is quite exceptional. In most cases, this relationship remains subjective and is no more than inner conviction. Several means are at our disposal to achieve causal assessment: spontaneous reporting, clinical trials, cohorts with and without controls, and case-control studies, with each having advantages and limitations. The search for casualty in pharmacovigilance is a necessary scientific goal, but a high degree of suspicion may be all that is necessary to withdraw a drug from the market if it is suspected of causing serious adverse effects.

Mesh:

Year:  1993        PMID: 8240728     DOI: 10.2165/00002018-199309030-00008

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  22 in total

1.  What do we mean by usually?

Authors:  N Sarkies
Journal:  Lancet       Date:  1980-06-14       Impact factor: 79.321

2.  Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-22

3.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

4.  Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions.

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-12

5.  [Is rechallenge necessary for complete imputability? Comparative value of 7 methods of determining imputability].

Authors:  E Loupi; A C Ponchon; J J Ventre; J Descotes; J C Evreux
Journal:  Therapie       Date:  1984 Sep-Oct       Impact factor: 2.070

6.  Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system.

Authors:  A C Rossi; D E Knapp
Journal:  JAMA       Date:  1984 Aug 24-31       Impact factor: 56.272

7.  [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods].

Authors:  J C Péré; M H Godin; B Bégaud; F Haramburu; H Albin
Journal:  Therapie       Date:  1985 Sep-Oct       Impact factor: 2.070

8.  [Bayesian approach to the imputability of undesirable phenomena to drugs].

Authors:  M Auriche
Journal:  Therapie       Date:  1985 Sep-Oct       Impact factor: 2.070

9.  Between never and always.

Authors:  R M Kenney
Journal:  N Engl J Med       Date:  1981-10-29       Impact factor: 91.245

10.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.

Authors: 
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

View more
  6 in total

1.  Causal or casual? The role of causality assessment in pharmacovigilance.

Authors:  R H Meyboom; Y A Hekster; A C Egberts; F W Gribnau; I R Edwards
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

Review 2.  Health risks of herbal remedies.

Authors:  P A De Smet
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 3.  A risk-benefit assessment of growth hormone use in children.

Authors:  S L Blethen; M H MacGillivray
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

4.  Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital.

Authors:  Marieke Grenouillet-Delacre; Hélène Verdoux; Nicholas Moore; Françoise Haramburu; Ghada Miremont-Salamé; Gabriel Etienne; Philip Robinson; Didier Gruson; Gilles Hilbert; Claude Gabinski; Bernard Bégaud; Mathieu Molimard
Journal:  Intensive Care Med       Date:  2007-07-25       Impact factor: 17.440

Review 5.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

6.  Antibiotics and allergic disorders in childhood.

Authors:  Sue Jordan; Mel Storey; Gareth Morgan
Journal:  Open Nurs J       Date:  2008-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.